Literature DB >> 21362521

Abdominal pediatric cancer surveillance using serial computed tomography: evaluation of organ absorbed dose and effective dose.

Diana Lam1, Sandra L Wootton-Gorges, John P McGahan, Robin Stern, John M Boone.   

Abstract

Computed tomography (CT) is used extensively in cancer diagnosis, staging, evaluation of response to treatment, and in active surveillance for cancer reoccurrence. A review of CT technology is provided, at a level of detail appropriate for a busy clinician to review. The basis of x-ray CT dosimetry is also discussed, and concepts of absorbed dose and effective dose (ED) are distinguished. Absorbed dose is a physical quantity (measured in milligray [mGy]) equal to the x-ray energy deposited in a mass of tissue, whereas ED uses an organ-specific weighting method that converts organ doses to ED measured in millisieverts (mSv). The organ weighting values carry with them a measure of radiation risk, and so ED (in mSv) is not a physical dose metric but rather is one that conveys radiation risk. The use of CT in a cancer surveillance protocol was used as an example of a pediatric patient who had kidney cancer, with surgery and radiation therapy. The active use of CT for cancer surveillance along with diagnostic CT scans led to a total of 50 CT scans performed on this child in a 7-year period. It was estimated that the patient received an average organ dose of 431 mGy from these CT scans. By comparison, the radiation therapy was performed and delivered 50.4 Gy to the patient's abdomen. Thus, the total dose from CT represented only 0.8% of the patient's radiation dose.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21362521      PMCID: PMC3286492          DOI: 10.1053/j.seminoncol.2010.11.009

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  12 in total

Review 1.  Dosimetry for optimisation of patient protection in computed tomography.

Authors:  K A Jessen; P C Shrimpton; J Geleijns; W Panzer; G Tosi
Journal:  Appl Radiat Isot       Date:  1999-01       Impact factor: 1.513

Review 2.  Computed tomography--an increasing source of radiation exposure.

Authors:  David J Brenner; Eric J Hall
Journal:  N Engl J Med       Date:  2007-11-29       Impact factor: 91.245

3.  Improved estimates of cancer site-specific risks for A-bomb survivors.

Authors:  David Pawel; Dale Preston; Donald Pierce; John Cologne
Journal:  Radiat Res       Date:  2008-01       Impact factor: 2.841

4.  CT scanner dosimetry.

Authors:  P C Shrimpton; S Edyvean
Journal:  Br J Radiol       Date:  1998-01       Impact factor: 3.039

5.  Estimated risks of radiation-induced fatal cancer from pediatric CT.

Authors:  D Brenner; C Elliston; E Hall; W Berdon
Journal:  AJR Am J Roentgenol       Date:  2001-02       Impact factor: 3.959

6.  Relationships between physical dose quantities and patient dose in CT.

Authors:  N Hidajat; J Mäurer; R J Schröder; A Nunnemann; M Wolf; K Pauli; R Felix
Journal:  Br J Radiol       Date:  1999-06       Impact factor: 3.039

Review 7.  The ICRP protection quantities, equivalent and effective dose: their basis and application.

Authors:  J D Harrison; C Streffer
Journal:  Radiat Prot Dosimetry       Date:  2007-11-14       Impact factor: 0.972

8.  Radiation doses and risks in chest computed tomography examinations.

Authors:  Walter Huda
Journal:  Proc Am Thorac Soc       Date:  2007-08-01

9.  Computing effective doses to pediatric patients undergoing body CT examinations.

Authors:  Walter Huda; Kent M Ogden
Journal:  Pediatr Radiol       Date:  2008-01-15

10.  Computed tomography use in a tertiary care university hospital.

Authors:  John M Boone; James A Brunberg
Journal:  J Am Coll Radiol       Date:  2008-02       Impact factor: 5.532

View more
  1 in total

1.  Detection of Relapse by Tumor Markers Versus Imaging in Children and Adolescents With Nongerminomatous Malignant Germ Cell Tumors: A Report From the Children's Oncology Group.

Authors:  Adriana Fonseca; Caihong Xia; Armando J Lorenzo; Mark Krailo; Thomas A Olson; Farzana Pashankar; Marcio H Malogolowkin; James F Amatruda; Deborah F Billmire; Carlos Rodriguez-Galindo; A Lindsay Frazier; Furqan Shaikh
Journal:  J Clin Oncol       Date:  2018-12-21       Impact factor: 44.544

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.